Anavex Life Sciences Corp (AVXL)

[boi568]

If it's difficult to note changes over Zoom, that has to work against showing efficacy. Each arm wouldn't change much, less opportunity for separation.

The 2:1 ratio can be considered a design flaw; virtual visits a design flaw unless compelled by quarantines, in which case it's bad luck. Either way, if the trial failed in this way, it's not a hit on the drug 2-73, but the circumstances of the trial.